Provided by Tiger Fintech (Singapore) Pte. Ltd.

Imunon, Inc.

0.8815
+0.02152.50%
Pre-market: 0.89990.0184+2.09%08:00 EDT
Volume:48.68K
Turnover:41.62K
Market Cap:12.78M
PE:-0.54
High:0.8996
Open:0.8600
Low:0.8316
Close:0.8600
Loading ...

Strong Potential for Imunon’s IMNN-001 in Advanced Ovarian Cancer: Promising OVATION 2 Study Results

TIPRANKS
·
11 Dec 2024

Imunon Is Maintained at Buy by D. Boral Capital

Dow Jones
·
10 Dec 2024

Imunon Inc - Imunon Remains on Track to Initiate Phase 3 Pivotal Trial of Imnn-001 in Q1 2025

THOMSON REUTERS
·
10 Dec 2024

Imunon Inc - No Change in Imnn-001 Favorable Safety Profile

THOMSON REUTERS
·
10 Dec 2024

Imunon Announces Continued Strong Improvement in Overall Survival Data From Randomized Phase 2 Ovation 2 Study of Imnn-001

THOMSON REUTERS
·
10 Dec 2024

Imunon Inc - Median Overall Survival Increased From 11 to 13 Months in Imnn-001 Group

THOMSON REUTERS
·
10 Dec 2024

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

GlobeNewswire
·
10 Dec 2024

IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…

Zacks Small Cap Research
·
25 Nov 2024

BRIEF-IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA

Reuters
·
25 Nov 2024

Imunon announces results from End-of-Phase 2 meeting with FDA for IMNN-001

TIPRANKS
·
25 Nov 2024

Imunon Inc - Imnn-001 Treatment Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
25 Nov 2024

Imunon Inc - Announces FDA Support for Phase 3 Study of Imnn-001

THOMSON REUTERS
·
25 Nov 2024

Imunon Announces Results From Its End-of-Phase 2 Meeting With the FDA for Its Lead Imnn-001 Clinical Program in Advanced Ovarian Cancer

THOMSON REUTERS
·
25 Nov 2024

Imunon Inc - to Initiate 500-Patient Phase 3 Trial in Q1 2025

THOMSON REUTERS
·
25 Nov 2024

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

GlobeNewswire
·
25 Nov 2024

IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial

Zacks Small Cap Research
·
11 Nov 2024

Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...

GuruFocus.com
·
08 Nov 2024

Imunon Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Imunon presents data from Phase 2 OVATION 2 clinical trial

TIPRANKS
·
07 Nov 2024

Imunon Presents Positive Data From Phase 2 Ovation 2 Clinical Trial of Imnn-001 in Advanced Ovarian Cancer at SITC 39TH Annual Meeting

THOMSON REUTERS
·
07 Nov 2024